Arne Östman
Uppsala University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Arne Östman.
Molecular and Cellular Biology | 2004
Camilla Persson; Catrine Sävenhed; Annie Bourdeau; Michel L. Tremblay; Boyka Markova; Frank-D. Böhmer; Fawaz G. Haj; Benjamin G. Neel; Ari Elson; Carl-Henrik Heldin; Lars Rönnstrand; Arne Östman; Carina Hellberg
ABSTRACT The platelet-derived growth factor (PDGF) β receptor mediates mitogenic and chemotactic signals. Like other tyrosine kinase receptors, the PDGF β receptor is negatively regulated by protein tyrosine phosphatases (PTPs). To explore whether T-cell PTP (TC-PTP) negatively regulates the PDGF β receptor, we compared PDGF β receptor tyrosine phosphorylation in wild-type and TC-PTP knockout (ko) mouse embryos. PDGF β receptors were hyperphosphorylated in TC-PTP ko embryos. Fivefold-higher ligand-induced receptor phosphorylation was observed in TC-PTP ko mouse embryo fibroblasts (MEFs) as well. Reexpression of TC-PTP partly abolished this difference. As determined with site-specific phosphotyrosine antibodies, the extent of hyperphosphorylation varied among different autophosphorylation sites. The phospholipase Cγ1 binding site Y1021, previously implicated in chemotaxis, displayed the largest increase in phosphorylation. The increase in Y1021 phosphorylation was accompanied by increased phospholipase Cγ1 activity and migratory hyperresponsiveness to PDGF. PDGF β receptor tyrosine phosphorylation in PTP-1B ko MEFs but not in PTPε ko MEFs was also higher than that in control cells. This increase occurred with a site distribution different from that seen after TC-PTP depletion. PDGF-induced migration was not increased in PTP-1B ko cells. In summary, our findings identify TC-PTP as a previously unrecognized negative regulator of PDGF β receptor signaling and support the general notion that PTPs display site selectivity in their action on tyrosine kinase receptors.
Oncogene | 2006
K K Balavenkatraman; Enrico Jandt; K Friedrich; T Kautenburger; B L Pool-Zobel; Arne Östman; Frank-D. Böhmer
The transmembrane protein-tyrosine phosphatase (PTP) DEP-1 (density-enhanced phosphatase) is a candidate tumor suppressor in the colon epithelium. We have explored the function of DEP-1 in colon epithelial cells by inducible re-expression in a DEP-1-deficient human colon cancer cell line. Density-enhanced phosphatase-1 re-expression led to profound inhibition of cell proliferation and cell migration, and was associated with cytoskeletal rearrangements. These effects were dependent on the PTP activity of DEP-1 as they were not observed with cells expressing the catalytically inactive DEP-1 C1239S variant. shRNA-mediated suppression of DEP-1 in a colon epithelial cell line with high endogenous DEP-1 levels enhanced proliferation, further supporting the antiproliferative function of DEP-1. Nutrients, which are considered to be chemoprotective with respect to colon cancer development, including butyrate, green tea and apple polyphenols, had the capacity to elevate transcription of endogenous DEP-1 mRNA and expression of DEP-1 protein. Upregulation of DEP-1 expression, and in turn inhibition of cell growth and migration may present a previously unrecognized mechanism of chemoprevention by nutrients.
Nucleic Acids Research | 2008
Luchezar Karagyozov; Rinesh Godfrey; Sylvia-Annette Böhmer; Astrid Petermann; Sebastian Hölters; Arne Östman; Frank-D. Böhmer
Analysis of the human protein-tyrosine phosphatase (PTP) PTPRJ mRNA detected three in-frame AUGs at the 5′-end (starting at nt +14, +191 and +356) with no intervening stop codons. This tandem AUG arrangement is conserved between humans and the mouse and is unique among the genes of the classical PTPs. Until now it was assumed that the principal open reading frame (ORF) starts at AUG356. Our experiments showed that: (i) translation of the mRNA synthesized under the PTPRJ promoter starts predominantly at AUG191, leading to the generation of a 55 amino acid sequence preceding the signal peptide; (ii) the longer form is being likewise correctly processed into mature PTPRJ; (iii) the translation of the region between AUG191 and AUG356 inhibits the overall expression, a feature which depends on the sequence of the encoded peptide. Specifically, a sequence of 13 amino acids containing multiple arginine residues (RRTGWRRRRRRRR) confers the inhibition. In the absence of uORF these previously unrecognized characteristics of the 5′-end of the mRNA present a novel mechanism to suppress, and potentially to regulate translation.
Archive | 2005
Tobias Sjöblom; Kristian Pietras; Arne Östman; Carl-Henrik Heldin
Platelet-derived growth factor (PDGF) is a family of isoforms that stimulate the growth, survival, and motility of fibroblasts, smooth muscle cells, and other cell types. PDGF was originally identified in human platelets and purified from this source; however, subsequent studies have shown that PDGF is synthesized by a number of different cell types. PDGF has important roles in the regulation of growth and differentiation of various mesenchymal cell types during embryonal development. In the adult, PDGF stimulates wound healing and also regulates the homeostasis of the connective tissue compartment. Overactivity of PDGF or constitutive activation of PDGF receptors has been implicated in several disorders, including malignancies, atherosclerosis, and fibrotic conditions. Therefore, much effort has recently been devoted to the development of specific and efficient PDGF antagonists. This review will focus on the validation of PDGF antagonists in animal models and on the initial clinical studies in which PDGF antagonists have been used to treat patients.
Archive | 2002
Ralf Brandt; Elisabeth Buchdunger; Carl-Henrik Heldin; Arne Östman; Kristian Pietras; Terence O'reilly; John David Rothermel; Peter Traxler; Markus Wartmann
Archive | 2013
Arne Östman; Carl-Henrik Heldin
Archive | 2008
Ralf Brandt; Elisabeth Buchdunger; Carl-Henrik Heldin; Arne Östman; Kristian Pietras; Terence O'reilly; John David Rothermel; Peter Traxler; Markus Wartmann
GBM Annual Spring meeting Mosbach 2006 | 2006
Frank-D. Böhmer; Irene Weibrecht; Annette Böhmer; Kai Kappert; Arne Östman
Acta oncol. bras | 2004
Carl-Henrik Heldin; Arne Östman
Archive | 2002
Ralf Brandt; Elisabeth Buchdunger; Carl-Henrik Heldin; Arne Östman; Kristian Pietras; Terence O'reilly; John David Rothermel; Peter Traxler; Markus Wartmann